NPCE NeuroPace Inc
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1528287 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY21.1%
TTM EPS YoY25.3%
Revenue 3-yr CAGR16.3%
Net income 3-yr CAGR—
Margins
Gross margin81.4%
Operating margin-15.4%
Net margin-20.0%
FCF margin-13.1%
EBITDA margin-15.0%
Returns
ROE-126.1%
ROA-18.7%
ROIC (approx.)-19.7%
Asset turnover0.94x
Leverage & solvency
Liabilities / assets87.9%
Debt / equity5.15x
Current ratio5.26x
Interest coverage-2.34x
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $99.99M | $79.91M | $65.42M | $45.52M | $45.18M |
| Cost of revenue | $22.77M | $20.82M | $17.30M | $13.03M | $11.75M |
| Gross profit | $77.22M | $59.09M | $48.12M | $32.49M | $33.44M |
| R&D expense | $27.89M | $23.65M | $20.78M | $21.95M | $18.21M |
| SG&A expense | $19.09M | $17.43M | $54.52M | $51.34M | $38.96M |
| Operating income | -$16.34M | -$21.67M | -$27.17M | -$40.79M | -$23.74M |
| Interest expense | $7.46M | $8.80M | $8.52M | $7.53M | $7.41M |
| Income tax | $0 | — | — | — | — |
| Net income | -$21.46M | -$27.14M | -$32.96M | -$47.08M | -$36.08M |
| EBITDA | -$16.10M | -$21.46M | -$27.00M | -$40.53M | -$23.44M |
| EPS (basic) | -0.66 | -0.93 | -1.27 | -1.91 | -2.17 |
| EPS (diluted) | -0.66 | -0.93 | -1.27 | -1.91 | -2.17 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | — | — |
| Weighted avg. shares (diluted) | 32.72M | 29.13M | 25.85M | 24.59M | 16.61M |
| Balance sheet | |||||
| Cash & equivalents | $21.69M | $13.55M | $18.18M | $6.73M | $19.31M |
| Short-term investments | $39.37M | $39.33M | $48.40M | $70.80M | $96.40M |
| Receivables | $12.94M | $12.85M | $12.31M | $7.48M | $7.09M |
| Inventory | $14.86M | $13.38M | $11.21M | $9.71M | $7.82M |
| Current assets | $94.07M | $81.34M | $92.72M | $97.71M | $132.82M |
| PP&E, net | $1.12M | $1.05M | $1.00M | $1.06M | $603,000 |
| Total assets | $105.56M | $94.65M | $107.65M | $114.11M | $133.56M |
| Current liabilities | $17.81M | $15.16M | $16.23M | $10.98M | $9.30M |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | $58.88M | $59.52M | $56.95M | $52.91M | $49.85M |
| Total debt | $58.88M | $59.52M | $56.95M | $52.91M | $49.85M |
| Total liabilities | $86.53M | $86.63M | $87.00M | $79.33M | $60.06M |
| Shareholders' equity | $19.03M | $8.01M | $20.65M | $34.78M | $73.50M |
| Net debt | $37.19M | $45.97M | $38.77M | $46.19M | $30.54M |
| Shares outstanding | 33.57M | 30.15M | 27.82M | 25.05M | 24.45M |
| Cash flow statement | |||||
| Operating cash flow | -$11.01M | -$17.95M | -$19.70M | -$36.87M | -$24.58M |
| Capital expenditure | $332,000 | $306,000 | $173,000 | $603,000 | $384,000 |
| Free cash flow | -$11.34M | -$18.25M | -$19.87M | -$37.47M | -$24.96M |
| Investing cash flow | -$332,000 | $8.99M | $23.03M | $23.80M | -$85.40M |
| Financing cash flow | $19.60M | $4.33M | $8.13M | $490,000 | $102.53M |
| Depreciation & amortization | $238,000 | $207,000 | $172,000 | $267,000 | $296,000 |
| Stock-based compensation | $11.09M | $10.28M | $9.56M | $8.35M | $4.29M |
| Share buybacks | $49.55M | $0 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.